To the best of our knowledge this is the first study with large sample size conducted in Tunisia to investigate the association between TP53 Arg72Pro polymorphism and risk of CLL and correlate with clinical and hematological parameters. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.